USP7 and plasma cell myeloma: In support of this notion, USP7 selective inhibitors have been found to significantly repress the growth of multiple tumor xenograft models in immunodeficient mice, including multiple myeloma, B cell leukemia, and neuroblastoma; in these studies, decreased tumor volume translated into increased survival of the tumor-implanted mice [21, 24, 49].